Compare AVNW & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNW | FHTX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.0M | 323.4M |
| IPO Year | 2007 | 2020 |
| Metric | AVNW | FHTX |
|---|---|---|
| Price | $15.84 | $4.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $34.50 | $11.50 |
| AVG Volume (30 Days) | ★ 236.3K | 101.4K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $243,858,000.00 | $30,909,000.00 |
| Revenue This Year | $5.59 | $8.89 |
| Revenue Next Year | $7.03 | $20.13 |
| P/E Ratio | $54.43 | ★ N/A |
| Revenue Growth | 0.56 | ★ 36.75 |
| 52 Week Low | $13.92 | $3.27 |
| 52 Week High | $27.02 | $6.95 |
| Indicator | AVNW | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.35 | 37.98 |
| Support Level | N/A | $3.65 |
| Resistance Level | $23.18 | $5.82 |
| Average True Range (ATR) | 1.16 | 0.29 |
| MACD | -0.69 | -0.07 |
| Stochastic Oscillator | 20.14 | 21.26 |
Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.